Originally Aired: January 21, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Immune checkpoint inhibitors have significantly improved the survival of patients with various types of cancers, yet most advanced cancer patients will need additional treatment options. Intratumoral myeloid dendritic cells play a pivotal role in reinvigorating the cancer-immunity cycle and re-licensing antitumor cytotoxic T lymphocytes. In this exciting new webinar co-hosted by GEN and Clinical OMICs, we will explore the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we will hear how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from:
Julia Katharina Schwarze, MD
Department of Medical Oncology
University Hospital Brussels
Angela Vasaturo, PhD
Senior Field Applications Scientist